April 1981

Effect on Growth in Pemoline-Treated Children With Attention Deficit Disorder

Author Affiliations

From Abbott Laboratories, North Chicago, Ill (Drs Friedmann and Carr and Mr Thomas); the Child Study Center, University of Arkansas, Little Rock (Drs Elders and Ringdahl); and the Fels Research Institute, Wright State University School of Medicine, Yellow Springs, Ohio (Dr Roche).

Am J Dis Child. 1981;135(4):329-332. doi:10.1001/archpedi.1981.02130280019007

• The growth of 22 children with attention deficit disorder (ADD) was monitored longitudinally for up to four years. Each child received at least one year of continuous, successful pemoline (Cylert) therapy, after which drug "vacations" were allowed. The effective dosage of pemoline ranged from 56 to 150 mg/day during the first year of treatment. Stature and weight measurements at six-month intervals were matched to those of paired "normal" children from the Fels Longitudinal Study. Significant deficits were observed for mean weight change at six and 12 months after baseline, and for mean stature change at 12 and 18 months after baseline. However, all subsequent six-month results up to four years did not differ significantly between the two groups. These results show a temporary retardation in the rate of growth in weight and stature with later catch-up growth in children treated with pemoline.

(Am J Dis Child 1981;135:329-332)